Pfizer realignment

Quote

anonymous

Guest
We could see this coming. Quote Ab from the August 1 Q 3 earnings conference

Q2 2023 Pfizer Inc Earnings Call on August 01, 2023 / 2:00PM (q4cdn.com)

"But given the uncertainty, we are also preparing to have the ability to adjust our 2024 total cost base to align with various future COVID-19 disease -- revenue scenarios. In fact, we've already identified specific areas where we can make adjustments, primarily within our COVID-19 cost base, if demand comes in lower than expected."
 
Yes, but those of us who have been in the trenches already know that interest and demand are low,

Patient resistance to treatment is increasing and customers are tired of trying to convince patients to get boosted and treated. Not unlike the era of smoking nicotine patches where Doctors gave up on trying to convince their patients for fear of losing them.
.
The latest variants of COVID while quite infectious do not seem to cause disease a severe as previously seen.
So while hospitalizations are up (by as much as 19%) it is from a very low baseline (lowest since the very beginning of the COVID pandemic in 2020) so the numbers are modest.

In addition, a number of MDs have expressed their own anti-vaccine views.

I'd guess that the Pfizer COVID franchise numbers will continue to look lousy.
 
Look at the bright side. If you lose your job with Paxlovid, you can always join the new Ashfield Pfizer contract to relaunch Pfizer’s 20 year old Cardiomyopathy drug to treat those harmed by their own COVID vaccine. This is no joke. Recruiting as we speak.
 


Write your reply...
Top Bottom
Back
Quote